INS and type 2 diabetes mellitus: These assumptions were used in lieu of clinical data informing changes in HbA1c and BMI on initiation of SGLT-2 inhibitor or basal insulin therapy in populations previously receiving metformin and GLP-1 receptor agonist therapy, and this remains the key limitation in modelling more complex treatment algorithms for type 2 diabetes.